FDA Approves Dupilumab for Treatment of Prurigo Nodularis

In phase 3 trials, patients showed clinically meaningful reductions in itchiness and skin lesions with dupilumab compared with placebo.
Medscape Medical News

source https://www.medscape.com/viewarticle/981630?src=rss